VYNE Therapeutics jumps on positive trial data, funding plan

YARROW BIOSCIENCE

30/10/2023 11:40

** Vyne Therapeutics' shares  VYNE.O  rise 14% to $2.55
premarket
    ** Drug developer reports positive data from early-stage
trial of drug in patients with skin condition called
non-segmental vitiligo
    ** Co says data from animal study of its oral drug to treat
psoriasis and rheumatoid arthritis also showed a positive effect
    ** Vyne also signs an $88 mln private placement funding deal
with certain healthcare-focused institutional investors
    ** Up to Friday's close, stock had fallen ~17% YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))